Oncternal Therapeutics (ONCT)
(Delayed Data from NSDQ)
$1.50 USD
+0.04 (2.74%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $1.50 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.50 USD
+0.04 (2.74%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $1.50 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Zacks News
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 4.62% and 233.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Stevanato Group (STVN) Q2 Earnings Match Estimates
by Zacks Equity Research
Stevanato (STVN) delivered earnings and revenue surprises of 0% and 1.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of -25.88% and 0.88%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 1.74% and 223.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Oncternal Therapeutics (ONCT) Rating Upgrade to Buy
by Zacks Equity Research
Oncternal Therapeutics (ONCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Analysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oncternal Therapeutics (ONCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Oncternal Therapeutics (ONCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -0.65% and 74.71%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 92.31% and 77.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Q4 Earnings Lag Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of -6.77% and 1.04%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 11.76% and 49.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 9.09% and 23.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 4.76% and 1.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Viatris' (VTRS) Q1 results are likely to be impacted by competitive pressure. With the Biocon deal closed, investors await its impact on first-quarter sales.
United Therapeutics (UTHR) Q1 Earnings Beat Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 11.72% and 1.46%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Nektar Therapeutics (NKTR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oncternal Therapeutics (ONCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Oncternal Therapeutics (ONCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals
by Zacks Equity Research
bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals are included in this Analyst Blog.
Biotech Stock Roundup: BLUE Announces Q4 Results, ONCT, ASND & RNA Fall on Updates
by Zacks Equity Research
Earnings and pipeline updates from bluebird bio (BLUE) and Avidity (RNA) are the key highlights for the biotech sector.
Oncternal (ONCT) Down on Restructuring Plan to Extend Runway
by Zacks Equity Research
Oncternal (ONCT) closes the development program for zilovertamab to extend its cash runway into 2025. Shares are down on the same.
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -9.52% and 7.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Oncternal Therapeutics (ONCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Oncternal Therapeutics (ONCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Corcept Therapeutics (CORT) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of -39.13% and 0.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 5.83% and 2%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Esperion Therapeutics (ESPR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 12.64% and 5.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?